Ocular Therapeutix Inc (OCUL)

[Mr_Popeye]

Older article from Seeking Alpha but still relevant.

Ocular Therapeutix (NASDAQ:OCUL) is initiated with a big $35 price target (it currently trades at just over $7.00 a share) over at Cantor Fitzgerald today. Earlier this year, the company resubmitted its New Drug Application {NDA} to the FDA seeking approval of DEXTENZA (dexamethasone insert) 0.4 mg for the treatment of ocular pain after ophthalmic surgery. I like this name and it is a recent addition to the model-20 stock Insiders Forum portfolio as the stock has an attractive risk/reward profile and recent insider buying. However, the company also just did a $25 million funding raise through a secondary offering and sometimes analysts can be more bullish on a concern in connection with this sort of event. We will make the full investment analysis on Ocular available next week via The Insiders Forum. Just choose to be a real-time follower of the Insiders Forum, and you will automatically get that full analysis when it comes out early next week.